WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and ...
NEW YORK--(BUSINESS WIRE)--The New York Times Company announced today that Arthur Golden has been appointed to its Board of Directors, effective January 1, 2021. Mr. Golden, 64, a fourth-generation ...
Director Arthur F. Golden recently purchased 9868 shares of Turn Therapeutics Inc. NASDAQ:TTRX common stock at prices ranging from $3.25 to $3.50, inclusive, in a transaction dated November 24, 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback